RBC Capital cuts EyePoint stock price target on trial miss

EyePoint shares fell 85% at the close, from $2.99 to $0.44, after Duravyu failed to meet the primary non-inferiority endpoint in either pivotal wet AMD study. RBC cut its price target to $1.00 from $5.00 and kept a Sector Perform rating; several other firms also downgraded the stock, with Chardan reducing its estimated approval probability to 10% from 60%. EyePoint reported $118 million in cash and maintained its runway guidance into Q4 2027, while considering options for wet AMD and awaiting a diabetic macular edema readout approximately one year away.

Analysis

The key repricing is not simply the loss of wAMD upside: failure in both pivotal studies weakens confidence in Duravyu’s broader development platform, so the DME thesis now needs indication-specific evidence rather than extrapolation from management conviction. Conversely, wAMD failure does not establish that DME will fail; the biology and trial design differ, leaving a genuine but binary catalyst roughly a year out.

Near term, the stated cash runway reduces pressure for an immediate financing, but it is not a reliable valuation floor without burn rate, liabilities, and expected trial costs. Verify those items and whether strategic prioritization changes spending. The steep selloff and analyst downgrades may already capture much of the wAMD reset; shorting here carries squeeze risk and leaves substantial exposure to favorable DME data. Established ophthalmology franchises, including Regeneron and Roche, could gain only if clinicians or investors infer a wider competitive advantage; there is not yet evidence of near-term share transfer.

Over 1–3 months, watch for trial-design, regulatory, and spending detail at the next company update. Over 6–18 months, DME data is the principal value inflection. The bearish thesis is falsified by convincing DME efficacy and safety data, while deterioration in cash runway or a further reduction in program scope would reinforce it. RSI or a cash-based comparison alone is not a fundamental buy signal.

Key Decisions for Investors

• Do not chase the post-collapse move with a fresh short: the wAMD failure is material, but the remaining DME catalyst and possible relief rallies create asymmetric gap risk.
• For existing EYPT exposure, size to a binary clinical outcome and avoid averaging down until management clarifies DME trial design, development costs, and cash burn.
• Keep EYPT on a catalyst watchlist rather than initiating a long ahead of data; revisit only if interim evidence or the eventual DME readout supports efficacy and the runway remains intact.
• Monitor the next operational update for a shorter runway, reduced DME commitment, or regulatory feedback that constrains the program; any would strengthen the downside case. A credible DME signal would invalidate it.